FGP
DAWN

Freestone Grove Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Freestone Grove Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43 Buy
+2
New +$28 ﹤0.01% 922

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Freestone Grove Partners's DAWN Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 2 shares worth $43. The stake represents ﹤0.01% of the portfolio and ranks #922 among its holdings.

206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Freestone Grove Partners held 2 shares of Day One Biopharmaceuticals worth $43 as of Q1 2026.
  • Day One Biopharmaceuticals was a new Freestone Grove Partners position in Q1 2026.
  • Day One Biopharmaceuticals made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #922 holding.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.